Edition:
United States

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

109.69USD
4:00pm EDT
Change (% chg)

$-1.16 (-1.05%)
Prev Close
$110.85
Open
$110.43
Day's High
$110.79
Day's Low
$107.82
Volume
935,807
Avg. Vol
589,624
52-wk High
$153.14
52-wk Low
$83.09

Chart for

About

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI... (more)

Overall

Beta: 0.93
Market Cap(Mil.): $23,350.52
Shares Outstanding(Mil.): 210.65
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 60.89 15.95
EPS (TTM): -- -- --
ROI: -- 0.19 15.19
ROE: -- 2.32 13.87

FDA declines to approve J&J arthritis drug sirukumab

The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday.

10:38am EDT

CORRECTED-UPDATE 2-FDA declines to approve J&J arthritis drug sirukumab

Sept 22 The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday.

10:25am EDT

BRIEF-Incyte's baricitinib meets primary endpoint in phase 2 study of patients with moderate-to-severe atopic dermatitis

* Baricitinib meets primary endpoint in phase 2 study of patients with moderate-to-severe atopic dermatitis

Sep 14 2017

BRIEF-Incyte announces pricing of public offering of 4,945,000 shares

* Incyte announces pricing of public offering of 4,945,000 shares of common stock Source text for Eikon: Further company coverage:

Sep 08 2017

BRIEF-Incyte Q2 loss per share $0.06

* Incyte reports 2017 second-quarter financial results and updates on key clinical programs

Aug 01 2017

BRIEF-Lilly and Incyte provide update on baricitinib

* Incyte Corp - ‍length of time to a resubmission for New Drug Application(NDA) anticipated to be a minimum of 18 months​

Jul 25 2017

BRIEF-Incyte says first patient treated in Phase 3 clinical trial of itacitinib

* Incyte announces first patient treated in Phase 3 clinical trial of itacitinib for acute graft-versus-host disease

Jul 20 2017

BRIEF-Incyte says Japan Ministry of Health, Labor And Welfare grants marketing approval for Olumiant

* Japan ministry of health, labor and welfare (mhlw) grants marketing approval for olumiant® (baricitinib) for the treatment of rheumatoid arthritis

Jul 03 2017

BRIEF-Incyte Corp updates on Echo-202 trial of Incyte’s Epacadostat in combination with Merck’s Keytruda

* Updated data from Echo-202 trial of Incyte’s Epacadostat in combination with Merck’s Keytruda® (Pembrolizumab) demonstrate clinical activity across multiple tumor types

Jun 05 2017

Merck, Incyte immunotherapy combination effective in lung cancer study

A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small, ongoing study of patients with advanced lung cancer, according to data released on Wednesday.

May 18 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $35.51 -0.45
Abbott Laboratories (ABT.N) $52.61 +0.10
Amgen, Inc. (AMGN.OQ) $186.29 +0.53
Biogen Inc (BIIB.OQ) $317.51 -0.95
Roche Holding Ltd. (ROG.S) CHF250.00 +2.00
Roche Holding Ltd. (RO.S) CHF249.70 +1.70
Sanofi SA (SASY.PA) €84.64 +0.52

Earnings vs. Estimates